A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted.
Cytokine Growth Factor Rev
; 58: 49-50, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-927134
ABSTRACT
Previous studies of SARS-CoV-2 viral infection suggest that both the humoral and cytotoxic arms of the immune system are weak in patients with severe COVID-19 disease when compared to mild disease. A cytokine storm is also induced in severe disease. IL-15 has been shown to support the cytotoxic arm of the immune response. IL-21 has been shown to support both the cytotoxic and humoral arms of the immune response. In addition, in some settings, Il-21 has been shown to actually decrease IL-6 and TNF-alpha production, reducing the inflammatory proteins involved in the cytokine storm. Furthermore, in other settings, the combination of IL-15 and IL-21 has been shown to be more effective than either interleukin alone in promoting an effective immune response. Therefore, a clinical trial that examines the use of the combination of IL-15 and IL-21 for COVID-19 patients is warranted.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Clinical Trials as Topic
/
Interleukins
/
Interleukin-15
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Cytokine Growth Factor Rev
Journal subject:
Allergy and Immunology
/
Biochemistry
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS